LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

LLY

762.79

+0.4%↑

JNJ

174.31

-1.4%↓

ABBV

221.87

+0.84%↑

UNH

334.97

-1.8%↓

AZN

77.08

-0.7%↓

Search

REVOLUTION Medicines Inc

Închisă

SectorSănătate

45.22 2.73

Rezumat

Modificarea prețului

24h

Curent

Minim

43.98

Maxim

45.33

Indicatori cheie

By Trading Economics

Venit

-34M

-248M

EPS

-1.13

Marjă de profit

-74.379

Angajați

700

EBITDA

-24M

-261M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+59.37% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.8B

8.7B

Deschiderea anterioară

42.49

Închiderea anterioară

45.22

Sentimentul știrilor

By Acuity

17%

83%

103 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

REVOLUTION Medicines Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

18 sept. 2025, 23:56 UTC

Acțiuni populare

Stocks to Watch: FedEx, 22nd Century, Scholastic

18 sept. 2025, 22:01 UTC

Principalele dinamici ale pieței

22nd Century Group Shares Gain on Debt Repayment, New Capital

18 sept. 2025, 20:51 UTC

Achiziții, Fuziuni, Preluări

UPS Terminates Plan to Buy Estafeta

18 sept. 2025, 20:31 UTC

Câștiguri

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping -- Update

18 sept. 2025, 20:26 UTC

Câștiguri

FedEx 1Q Profit, Sales Rise on Improvement in U.S. Shipping

18 sept. 2025, 23:43 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 sept. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on U.S. Stock Gains, Weaker Yen -- Market Talk

18 sept. 2025, 23:43 UTC

Market Talk

Global Equities Roundup: Market Talk

18 sept. 2025, 23:40 UTC

Market Talk

Gold Edges Lower Amid Cautious Mood -- Market Talk

18 sept. 2025, 23:31 UTC

Market Talk

FedEx Says U.S. Demand Is Resilient -- Market Talk

18 sept. 2025, 22:03 UTC

Câștiguri

FedEx Expects Trade Environment to Create $1B Headwind in 2026, CFO Says

18 sept. 2025, 22:01 UTC

Câștiguri

FedEx CFO: Asia-to-U.S. Declines Drove $150M International Export Headwind

18 sept. 2025, 21:56 UTC

Câștiguri

Lennar Missed Revenue Estimates. The Stock Is Down. -- Barrons.com

18 sept. 2025, 21:54 UTC

Câștiguri

FedEx Focused on Demand From Southeast Asia, Europe Amid China Shipping Slowdown, Customer Chief Says

18 sept. 2025, 21:48 UTC

Câștiguri

FedEx International Export Volumes Declined, Especially on China-to-U.S. Lane, Exec Says

18 sept. 2025, 21:47 UTC

Câștiguri

FedEx Had 5% Increase in U.S. Domestic Average Daily Package Volume in 1Q, Customer Chief Says

18 sept. 2025, 21:17 UTC

Câștiguri

FedEx Profit, Sales Rise on Improvement in U.S. Shipping -- 2nd Update

18 sept. 2025, 21:07 UTC

Câștiguri

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

18 sept. 2025, 20:50 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

18 sept. 2025, 20:22 UTC

Achiziții, Fuziuni, Preluări

UPS Cites Inability of All Closing Conditions to Be Satisfied

18 sept. 2025, 20:22 UTC

Achiziții, Fuziuni, Preluări

United Parcel Service Terminates Plan to Buy Estafeta

18 sept. 2025, 20:20 UTC

Achiziții, Fuziuni, Preluări

Here's How Much the U.S. Has Made on Its Intel Stock Purchase -- Barrons.com

18 sept. 2025, 20:18 UTC

Câștiguri

Nucor Stock Falls After Earnings. Why Its Guidance Was Far Off Rival Steel Dynamics. -- Barrons.com

18 sept. 2025, 20:18 UTC

Câștiguri

Bullish Crushes Earnings. The Crypto Stock Pops. -- Barrons.com

18 sept. 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

18 sept. 2025, 20:07 UTC

Câștiguri

FedEx Earnings Were a Relief. The Stock Is Up. -- Barrons.com

18 sept. 2025, 20:03 UTC

Câștiguri

FedEx 1Q FedEx Freight Segment Revenue $2.26B >FDX

Comparație

Modificare preț

REVOLUTION Medicines Inc Așteptări

Obiectiv de preț

By TipRanks

59.37% sus

Prognoză pe 12 luni

Medie 71.24 USD  59.37%

Maxim 80 USD

Minim 37.91 USD

În baza a 15 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruREVOLUTION Medicines Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

15 ratings

15

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

40.67 / 41.96Suport & Rezistență

Termen scurt

Strong Bullish Evidence

Termen mediu

Strong Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

103 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat